BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Not Yet Opened 04-28 16:00:00 EDT

2.42

+0.45

+22.84%

盘后2.59

+0.17+7.02%

19:56 EDT

High2.50	Low2.23	Vol349.09K
Open2.23	D1 Closing1.97	Amplitude13.80%
Mkt Cap11.33M	Tradable Cap8.94M	Total Shares4.68M
T/O824.00K	T/O Rate9.45%	Tradable Shares3.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":2.42,"timestamp":1745870400000,"preClose":1.97,"halted":0,"volume":349088,"hourTrading":{"tag":"盘后","latestPrice":2.59,"preClose":2.42,"latestTime":"19:56 EDT","volume":16088,"amount":39900.99,"timestamp":1745884563000},"delay":0,"floatShares":3693720,"shares":4680005,"eps":-2.895954,"marketStatus":"Not Yet Opened","change":0.45,"latestTime":"04-28 16:00:00 EDT","open":2.23,"high":2.5018,"low":2.23,"amount":824004.420512,"amplitude":0.13797,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.895954,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745913600000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1.97,"preHourTrading":{"tag":"盘前","latestPrice":2.29,"preClose":1.97,"latestTime":"09:26 EDT","volume":30533,"amount":67860.01080209999,"timestamp":1745846804937},"postHourTrading":{"tag":"盘后","latestPrice":2.59,"preClose":2.42,"latestTime":"19:56 EDT","volume":16088,"amount":39900.99,"timestamp":1745884563000},"volumeRatio":10.272068,"impliedVol":0.8044,"impliedVolPercentile":0.96},"requestUrl":"/m/hq/s/BCDA/tweets","defaultTab":"tweets","newsList":[{"id":"2531932632","title":"Director Richard M. Krasno Reports Acquisition of Common Shares of BioCardia Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2531932632","media":"Reuters","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531932632?lang=en_us&edition=full_marsco","pubTime":"2025-04-29 06:47","pubTimestamp":1745880432,"startTime":"0","endTime":"0","summary":"Richard M. Krasno, a director of BioCardia Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250428:nNDL9gbjL7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2527841216","title":"BRIEF-Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2527841216","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527841216?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 21:34","pubTimestamp":1744724068,"startTime":"0","endTime":"0","summary":"BRIEF-Biocardia Announces Positive Dsmb Review Of Cardiallo Allogeneic Cell Therapy For Heart Failure Phase 1/2 Clinical TrialApril 15 (Reuters) - BioCardia Inc BCDA.O:BIOCARDIA ANNOUNCES POSITIVE DSM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0J7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2527419612","title":"BioCardia’s CardiALLO Trial Advances After Safety Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2527419612","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527419612?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 20:59","pubTimestamp":1744721949,"startTime":"0","endTime":"0","summary":"The latest update is out from BioCardia ( ($BCDA) ). On April 15, 2025, BioCardia announced that the independent Data Safety Monitoring Board recom...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardias-cardiallo-trial-advances-after-safety-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardias-cardiallo-trial-advances-after-safety-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2527413040","title":"BioCardia Announces Positive Dsmb Review of Cardiallo Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2527413040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527413040?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 20:30","pubTimestamp":1744720218,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0J7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2527155324","title":"BioCardia Inc: Plans to Progress Trial to Enrollment of 39 Participants in United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2527155324","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527155324?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 20:30","pubTimestamp":1744720218,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250415:nFWN3QT0J7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2527415135","title":"BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2527415135","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527415135?lang=en_us&edition=full_marsco","pubTime":"2025-04-15 20:30","pubTimestamp":1744720200,"startTime":"0","endTime":"0","summary":"Independent Data Safety Monitoring Board (DSMB) recommends that the study proceeds as designed based on 30-day data safety assessment of participants treated in low dosage group. The company plans to ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/15/3061732/0/en/BioCardia-Announces-Positive-DSMB-Review-of-CardiALLO-Allogeneic-Cell-Therapy-for-Heart-Failure-Phase-1-2-Clinical-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2526273613","title":"BioCardia Says Emory University Enrolling Heart Patients for CardiAMP HF II Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2526273613","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526273613?lang=en_us&edition=full_marsco","pubTime":"2025-04-12 01:03","pubTimestamp":1744391004,"startTime":"0","endTime":"0","summary":"BioCardia  said Friday that Emory University School of Medicine in Atlanta has started enrolling patients with ischemic heart failure in the company's ongoing phase 3 CardiAMP HF II trial.The CardiAMP HF II therapy is a system designed for the harvest, processing and minimally invasive delivery of autologous mononuclear cells to the heart intended to enhance microvascular density and reduce fibrosis, the company said.The study will compare treatment with CardiAMP therapy to a placebo procedure with all patients on stable guideline directed medical therapy, the company said.Price: 1.95, Change: +0.02, Percent Change: +1.19","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BCDA","HF"],"gpt_icon":0},{"id":"2526698112","title":"BRIEF-Biocardia Initiates Patient Enrollment At Emory University School Of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2526698112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526698112?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 21:29","pubTimestamp":1744378177,"startTime":"0","endTime":"0","summary":"BRIEF-Biocardia Initiates Patient Enrollment At Emory University School Of MedicineApril 11 (Reuters) - BioCardia Inc BCDA.O:BIOCARDIA INITIATES PATIENT ENROLLMENT AT EMORY UNIVERSITY SCHOOL OF MEDICI","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nTUA6CKGWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2526988986","title":"BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing Cardiamp HF Ii Pivotal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2526988986","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526988986?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 21:15","pubTimestamp":1744377300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250411:nTUA6CKGWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2526666470","title":"BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2526666470","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526666470?lang=en_us&edition=full_marsco","pubTime":"2025-04-11 21:15","pubTimestamp":1744377300,"startTime":"0","endTime":"0","summary":"CardiAMP HF II is Evaluating the CardiAMP Cell Therapy Product for Treating Patients with Ischemic Heart Failure of Reduced Ejection Fraction and Elevated Markers of Cardiac Stress. Dr. Arshed Quyyumi, Professor of Medicine, Division of Cardiology, Department of Medicine, Emory University School of Medicine, and Co-Director of the Emory Clinical Cardiovascular Research Institute to Serve as Principal Investigator. SUNNYVALE, Calif., April 11, 2025  -- BioCardia, Inc.[Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announced today that Emory University School of Medicine in Atlanta Georgia is now enrolling patients with ischemic heart failure in the Company’s ongoing pivotal Phase III CardiAMP HF II trial. Emory University joins esteemed clinical sites throughout the United States participating in the study.Heart failure of reduced ejection fraction  is a clinical condition in which the output of blood ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-initiates-patient-enrollment-emory-131500625.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4208","HF","BCDAW","CMS","BCDA","LU2500361329.USD","LU2346227817.USD","LU2637428348.USD","BK4585","BK4588","BK4139","LU1894683348.USD","LU1894683264.USD"],"gpt_icon":0},{"id":"2524717674","title":"BioCardia’s Earnings Call Highlights Strong Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2524717674","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524717674?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 08:11","pubTimestamp":1743552678,"startTime":"0","endTime":"0","summary":"Biocardia (($BCDA)) has held its Q4 earnings call. Read on for the main highlights of the call. BioCardia’s recent earnings call revealed a general...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardias-earnings-call-highlights-strong-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardias-earnings-call-highlights-strong-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCDA"],"gpt_icon":0},{"id":"2524015959","title":"BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2524015959","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524015959?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 15:03","pubTimestamp":1743491003,"startTime":"0","endTime":"0","summary":"Total Expense: Decreased 35% year-over-year to $8.1 million in 2024 from $12.1 million in 2023.Research and Development Expense: Decreased 43% to $4.4 million in 2024 from $7.7 million in 2023.Selling, General and Administrative Expenses: Decreased 16% to $3.7 million in 2024 from $4.4 million in 2023.Net Loss: Decreased to $7.9 million in 2024 from $11.6 million in 2023.Net Cash Used in Operations: Approximately $8 million in 2024, down from approximately $10 million in 2023.Cash and Cash Equivalents: Ended the year with $2.4 million.GuruFocus has detected 7 Warning Signs with BCDA.For the complete transcript of the earnings call, please refer to the full earnings call transcript.BioCardia Inc  reported a significant reduction in mortality rates in their CardiAMP HF clinical trial, which is a positive outcome in a field where no current therapy reduces mortality.The CardiAMP HF trial showed a 47% relative risk reduction in heart death equivalents and a 16% relative risk reduction in m","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-inc-bcda-q4-2024-070323496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDAW","BCDA"],"gpt_icon":0},{"id":"2524976604","title":"BioCardia Clarifies Timing for CardiAMP-HF Results Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2524976604","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524976604?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 02:28","pubTimestamp":1743445699,"startTime":"0","endTime":"0","summary":"The latest announcement is out from BioCardia ( ($BCDA) ). On March 31, 2025, BioCardia, Inc. announced a clarification regarding the timing of its...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biocardia-clarifies-timing-for-cardiamp-hf-results-call?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biocardia-clarifies-timing-for-cardiamp-hf-results-call?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCDA","HF"],"gpt_icon":0},{"id":"2524973473","title":"BioCardia’s Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2524973473","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524973473?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 01:39","pubTimestamp":1743442740,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., March 31, 2025  -- BioCardia, Inc.[Nasdaq: BCDA],a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today clarifies that two-year CardiAMP-HF results will be addressed in a conference call scheduled for today, Monday, March 31, 2025 at 4:30pm EDT. The press release earlier this morning incorrectly noted the call would be held at 4:30pm PDT.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-conference-call-today-monday-173900142.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDA","BCDAW","BK4139"],"gpt_icon":0},{"id":"2523929505","title":"BioCardia's Ischemic HF Cell Therapy Trial Reached no 'Statistical Significance' in Primary Composite Efficacy Endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2523929505","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523929505?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 23:17","pubTimestamp":1743434228,"startTime":"0","endTime":"0","summary":"BioCardia  said Monday its two-year phase 3 trial of its CardiAMP cell therapy to treat ischemic heart failure in patients with reduced ejection fraction reached no 'statistical significance' in its primary composite efficacy endpoint.The double-blind randomized placebo-controlled trial, which involved 115 ischemic heart failure patients with reduced ejection fraction, maintained the patients on heart failure medication, while those treated with the CardiAMP minimally invasive cell therapy received a single dose adjunctive to medication.The company said the trial results indicated increased survival and reduced major adverse cardiac and cerebrovascular events were observed throughout the study.The company said it would share trial data with the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency to make the therapy available for physicians \"as soon as possible.\"Price: 2.55, Change: -0.25, Percent Change: -8.93","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BCDA","HF"],"gpt_icon":0},{"id":"2523458059","title":"BioCardia Phase 3 Cardiamp-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2523458059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523458059?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:00","pubTimestamp":1743422421,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE10H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2523945619","title":"Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2523945619","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523945619?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 20:00","pubTimestamp":1743422400,"startTime":"0","endTime":"0","summary":"Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significanceStatistica","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052241/0/en/Biocardia-Phase-3-CardiAMP-HF-Trial-of-Novel-Cardiac-Cell-Therapy-for-Ischemic-Heart-Failure-Shows-Increased-Survival-Decreased-Cardiac-Events-and-Improved-Quality-of-Life-at-Two-Y.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2346227817.USD","BCDA","HF","BK4139","LU2500361329.USD","LU1894683348.USD","LU1894683264.USD","BK4585","BK4588","LU2637428348.USD","CMS","BK4208"],"gpt_icon":0},{"id":"2522527927","title":"BioCardia Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag","url":"https://stock-news.laohu8.com/highlight/detail?id=2522527927","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522527927?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:02","pubTimestamp":1743159768,"startTime":"0","endTime":"0","summary":"AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.NasdaqCM:BCDA Earnings and Revenue History March 28th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue missed analyst estimates by 37%. Earnings per share  exceeded analyst estimates by 6.8%.Looking ahead, revenue is forecast to grow 83% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are up 8.5% from a week ago.Be aware that  BioCardia is showing  7 warning signs in our investment analysis and 4 of those shouldn't be ignored...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biocardia-full-2024-earnings-eps-110248237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BCDA","BCDAW"],"gpt_icon":0},{"id":"2522328355","title":"BioCardia Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522328355","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522328355?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:50","pubTimestamp":1743022224,"startTime":"0","endTime":"0","summary":"BioCardia Inc reports results for the quarter ended December 31 - Earnings SummaryBioCardia Inc BCDA.OQ reported a quarterly adjusted loss of 25 cents per share for the quarter ended December 31, high","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nL5N3Q923Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"gpt_icon":0},{"id":"2522361353","title":"BioCardia FY 2024 GAAP EPS $(2.90) Beats $(3.11) Estimate, Sales $58.00K Miss $91.50K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2522361353","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522361353?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 04:34","pubTimestamp":1743021249,"startTime":"0","endTime":"0","summary":"BioCardia (NASDAQ:BCDA) reported quarterly losses of $(2.90) per share which beat the analyst consensus estimate of $(3.11) by 6.75 percent.  The company reported quarterly sales of $58.00 thousand which missed the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44503748/biocardia-fy-2024-gaap-eps-2-90-beats-3-11-estimate-sales-58-00k-miss-91-50k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":0.3852},{"period":"1month","weight":-0.1357},{"period":"3month","weight":0.0614},{"period":"6month","weight":0.0211},{"period":"1year","weight":-0.5716},{"period":"ytd","weight":0.1101}],"compareEarnings":[{"period":"1week","weight":0.0719},{"period":"1month","weight":-0.0087},{"period":"3month","weight":-0.0888},{"period":"6month","weight":-0.0503},{"period":"1year","weight":0.0838},{"period":"ytd","weight":-0.0601}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.078472},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.026705},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.016712},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.049282},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.051537},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.041157},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.032675},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.106569},{"month":9,"riseRate":0.428571,"avgChangeRate":0.059679},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.068561},{"month":11,"riseRate":0.428571,"avgChangeRate":0.043567},{"month":12,"riseRate":0.428571,"avgChangeRate":0.005777}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction